In This Section

Program: Friday, February 20

Wednesday, Feb. 18 Thursday, Feb. 19 Saturday, Feb. 21

FRIDAY, FEBRUARY 20

Friday, February 20

Breakfast

7-8 a.m.

Keynote Session 3

8-9:20 a.m.

  • 8 a.m. | Introduction of Keynote Speaker
  • 8:05 a.m. | LAG-3: The third checkpoint inhibitor and its synergistic interactions with PD1
    Dario A. Vignali, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
  • 8:40 a.m. | Introduction of Keynote Speaker
  • 8:45 a.m. | Immunology of poorly-immunogenic tumor
    Lieping Chen, Yale University, New Haven, Connecticut

Break

9:20-9:30 a.m.

Major Symposia 5-6

9:30-11 a.m.

Major Symposium 5: New Breakthroughs in TCR Engineering

Session Chair: Owen N. Witte, University of California, Los Angeles, California

  • 9:35 a.m. | Cancer immunotherapy: Target, modality, and timing
    Owen N. Witte
  • 9:55 a.m. | Christopher A. Klebanoff, Memorial Sloan Kettering Cancer Center, New York, New York

Short talks selected from highly rated abstracts

Major Symposium 6: TILs and Maintenance of Immunity

Session Chair: Brian Gastman, Iovance Biotherapeutics, San Carlos, California

  • 9:35 a.m. | Parameswaran Hari, Obsidian Therapeutics, Cambridge, Massachusetts
  • 9:55 a.m. | Brian Gastman

Short talks selected from highly rated abstracts

Break

11-11:15 a.m.

Spotlight on Proffered Papers Session 2

11:15 a.m.-12 p.m.

Session Chair: Antoni Ribas, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California

Short talks selected from highly rated abstracts

Poster Session C / Exhibit Show / Lunch

12:15-3:15 p.m.

Major Symposia 7-8

3:15-4:45 p.m.

Major Symposium 7: In vivo T Cell Engineering – Are We There Yet?

Session Chair: Justin Eyquem, Gladstone-UCSF Institute of Genomic Immunology, San Francisco, California

  • 3:20 p.m. | Justin Eyquem
  • 3:40 p.m. | Kevin Friedman, Kelonia Therapeutics, Boston, Massachusetts
  • 4 p.m. | Haig Aghajanian, Capstan Therapeutics, San Diego, California

Major Symposium 8: Neuro-Psych-Immunology in IO

Session Chair: Lili Yang, University of California, Los Angeles, California

  • 3:20 p.m. | From brain to cancer: Harnessing serotonin and antidepressants for immunotherapy
    Lili Yang
  • 3:40 p.m. | Neuromediators in the tumor microenvironment: GABA modulates tumor immunity and impairs response to immunotherapy
    Wolf Herve Fridman, INSERM U1138, Paris, France

Short talks selected from highly rated abstracts

Break

4:45-5 p.m.

Spotlight Sessions 3-4

5-6:20 p.m.

Spotlight Session 3: Novel T-cell Engagers

Session Chair: Paresh Vyas, University of Oxford, Oxford, United Kingdom

  • 5:05 p.m. | Paresh Vyas
  • 5:25 p.m. | Patrick A. Baeuerle, Cullinan Therapeutics, Cambridge, Massachusetts

Short talks selected from highly rated abstracts

Spotlight Session 4: Systems Immunology

Session Chair: Garry P. Nolan, Stanford University School of Medicine, Stanford, California

  • 5:05 p.m. | Garry P. Nolan
  • 5:25 p.m. | A multiscale view of tumor ecosystems: From single-cell states to functional immune niches and communities
    Linghua Wang, The University of Texas MD Anderson Cancer Center, Houston, Texas

Short talks selected from highly rated abstracts

Evening off / Dinner on own

6:20 p.m.